Loading stock data…
ATRA
$8.34-1.59 (-16.01%)
Market ClosedLast close May 8
Atara Biotherapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Atara Biotherapeutics, Inc. in the Healthcare sector is trading at $8.34. The stock is currently 56% below its 52-week high of $19.14, remaining 18.7% below its 200-day moving average. Technical signals show overbought RSI of 70 and bullish MACD crossover, explaining why ATRA maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 70) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.34
Potential Downside
49.4%
Whystock Fair Value$4.22
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy pro...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$42.36M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
2.02
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-84.90%
Volume
Today's trading volume
2.89M
Recent News
FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive
Atara Biotherapeutics said the FDA outlined a potential pathway for resubmitting the tabelecleucel application after a recent Complete Response Letter. Key Investor TakeawaysAtara Biotherapeutics (NASDAQ:ATRA) said the FDA discussed a potential resubmission path for tabelecleucel following a Type A meeting.
Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise
We recently compiled a list of the 10 Best Cheap Stocks Under $10 to Buy in April. Atara Biotherapeutics, Inc. is among the best cheap stocks to buy. TheFly reported on March 17 that ATRA filed a prospectus to register the potential resale of up to 400,000 common shares by HCR Molag Fund, L.P. These […]
Atara Biotherapeutics: Q4 Earnings Snapshot
ATRA) on Monday reported a loss of $3.4 million in its fourth quarter. The Thousand Oaks, California-based company said it had a loss of 25 cents per share. The drug developer posted revenue of $1.6 million in the period.
Pierre Fabre seeks to revive US approval chances for spurned cell therapy
Ebvallo is one of a series of rare disease treatments recently turned back by the FDA amid shifting guidance that has surprised some companies and frustrated investors.
Top Midday Decliners
Travere Therapeutics (TVTX) said the US Food and Drug Administration extended the review timeline of